Author Archives: admin


Dr. Ruben A. Mesa of Arizona’s Mayo Clinic named new director of … – San Antonio Express-News (subscription)


San Antonio Express-News (subscription)
Dr. Ruben A. Mesa of Arizona's Mayo Clinic named new director of ...
San Antonio Express-News (subscription)
Dr. William Henrich, president of UT Health Science Center San Antonio, described Mesa as an international expert in myeloproliferative neoplasms, or MPNs, ...

and more »

Read the original here:
Dr. Ruben A. Mesa of Arizona's Mayo Clinic named new director of ... - San Antonio Express-News (subscription)

Stem Cells and Regenerative Medicine Global Summit – Technology Networks

The discovery of stem cell has revolutionized the medical world. Ever since the pioneering work of Canadian scientists, Dr. James Till and Dr. Ernest McCulloch, stem cell research has opened up doors to treatments for seemingly incurable conditions and set the groundwork for regenerative medicine.

To support stem cell translation and to help scientists, researchers, and industry members to stay ahead of this constantly evolving field, Clariden Global is proud to present Stem Cells and Regenerative Medicine Global Summit in Toronto, Canada, from 25th 27th September 2017.

The summit will showcase the latest innovations and breakthroughs in stem cell research and medical applications. You will discover the solutions to technical challenges in stem cell expansion, delivery, and integration, and find out how to address rejection and tumor risks of stem cell therapy. The event presents a premium platform for all participants to discover development progress of stem cell medical treatments.

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

Read the original here:
Stem Cells and Regenerative Medicine Global Summit - Technology Networks

Transplants using iPS cells put Riken specialist at forefront of regenerative medicine research – The Japan Times

When she entered medicine in the mid-1980s, Masayo Takahashi chose ophthalmology as her specialty, she said, because she wanted to have a family and thought the discipline would spare her from sudden work calls in the middle of the night, helping her best balance work and life.

Three decades later, the 55-year-old mother of two grown-up daughters is at the forefront of the nations even the worlds research into regenerative medicine.

In September 2014, she offered a ray of hope to scores of patients suffering from a severe eye condition when her team at the Riken institutes Center for Developmental Biology in Kobe succeeded in a world-first transplanting of cells made from induced pluripotent stem (iPS) cells into a human body.

The operation, conducted as a clinical study, involved creating a retinal sheet from iPS cells, which were developed by Shinya Yamanaka, a researcher at Kyoto University. His 2006 discovery of iPS cells, which can grow into any kind of tissue in the body, won him a Nobel Prize in 2012.

During the 2014 procedure, the retinal sheet was transplanted into a female patient in her 70s with age-related macular degeneration (AMD), an eye disorder that blurs the central field of vision and can lead to blindness. The research team used iPS cells made from the patients own skin cells.

Takahashi made history again in March when she and her team carried out the worlds first transplant of retina cells created from donor iPS cells stocked at Kyoto University. The time and cost necessary for the procedure has been significantly reduced by using the cells, which are made from super-donors, people with special white blood cell types that arent rejected by the immune systems of receiving patients.

Takahashi was in Tokyo last week to speak at the Foreign Press Center and later with The Japan Times. She recounted the highlights of her 25-year research and the numerous legal and other challenges she has overcome.

Takahashi points to the day she led that first iPS transplant surgery Sept. 12, 2014 as the high point of her career so far. Because she worked so hard leading up to the surgery to confirm the safety of the retinal cells, she said that when the operation was over, she was relieved and slept very well.

It wasnt the same for Yamanaka, who provided the stem cells to Takahashi, she said, chuckling. Yamanaka-sensei couldnt sleep well after the surgery because he didnt know about the safety of the cells very well. I should have convinced him.

Some researchers have expressed concern that iPS cell-derived cells have a higher risk of developing cancer. But Takahashi said she knew from the outset that the type her team was making, retinal pigment epithelium (RPE) cells, are extremely unlikely to cause tumors. RPE cells make up the pigmented layer of tissue that supports the light-sensitive cells of the retina.

People in the world think iPS cells are very dangerous because we modify the genes, she said. The retinal pigment epithelium cell is very safe. We knew it from the beginning because we have never seen a metastatic tumor from this cell. Ophthalmologists know very well that this cell is very safe and very good.

The Osaka native said she learned of and became fascinated by the possibility of using stem cells for eye diseases in the mid-1990s, when she took a year off from clinical practice at Kyoto University to work as a researcher at the Salk Institute in San Diego. She moved to Riken in 2006.

More than 2 years have passed since that first iPS surgery, but the transplanted cells remain intact. According to Takahashi, it was not the goal of the research from the outset to improve the eyesight of the patient, who suffered from a very severe case of AMD. Before the surgery, the patient required injections of drugs into her eyeball every two months, but her visual acuity was declining. After the surgery, her acuity stabilized, and more importantly, she is happy, feeling that her vision has brightened and widened, Takahashi said.

Many challenges remain, however, to advance the technology and make it commercially available. One of the issues is cost, Takahashi said, adding that it will take until around 2019 before the cost of the iPS treatment for AMD will fall below 10 million. The first surgery in 2014 cost about 100 million in total, much of which was spent to maintain the clean room and culture the cells.

Still, Takahashi sees a huge potential for iPS cell therapy in her field and beyond.

Every disease has potential to be treated by iPS cell-derived cells or ES (embryonic stem) cell-derived cells in the future, she said, responding to a question on the chances of iPS cells being used to treat ALS, a rare, degenerative neurological disease for which there is currently no cure.

She said she has learned through her experience that some patients are very happy with small improvements.

For ALS, at first, I thought, its a systemic, whole-body disease, so I didnt know how they can fix it, she said. But a doctor (who specializes in ALS) said, its OK, if one finger moves, its (still) OK. So I realized that some benefit will come from cell therapy.

A Matter of Health is a weekly series on the latest health research, technology or policy issues in Japan. It appears on Thursdays.

See the original post here:
Transplants using iPS cells put Riken specialist at forefront of regenerative medicine research - The Japan Times

Mitochondria behind blood cell formation – Phys.org – Phys.Org

June 13, 2017 Mitochondria are tiny, free-floating organelles inside cells. New Northwestern Medicine research has discovered that they play an important role in hematopoiesis, the bodys process for creating new blood cells. Credit: Northwestern University

New Northwestern Medicine research published in Nature Cell Biology has shown that mitochondria, traditionally known for their role creating energy in cells, also play an important role in hematopoiesis, the body's process for creating new blood cells.

"Historically, mitochondria are viewed as ATPenergyproducing organelles," explained principal investigator Navdeep Chandel, PhD, the David W. Cugell Professor of Medicine in the Division of Pulmonary and Critical Care Medicine. "Previously, my laboratory provided evidence that mitochondria can dictate cell function or fate independent of ATP production. We established the idea that mitochondria are signaling organelles."

In the current study, Chandel's team, including post-doctoral fellow Elena Ans, PhD, and graduate students Sam Weinberg and Lauren Diebold, demonstrated that mitochondria control hematopoietic stem cell fate by preventing the generation of a metabolite called 2-hydroxyglutarate (2HG). The scientists showed that mice with stem cells deficient in mitochondrial function cannot generate blood cells due to elevated levels of 2HG, which causes histone and DNA hyper-methylation.

"This is a great example of two laboratories complementing their expertise to work on a project," said Chandel, also a professor of Cell and Molecular Biology and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Paul Schumacker, PhD, professor of Pediatrics, Cell and Molecular Biology and Medicine, was also a co-author on the paper.

Chandel co-authored an accompanying paper in Nature Cell Biology, led by Jian Xu, PhD, at the University of Texas Southwestern Medical Center, which demonstrated that initiation of erythropoiesis, the production of red blood cells specifically, requires functional mitochondria.

"These two studies collectively support the idea that metabolism dictates stem cell fate, which is a rapidly evolving subject matter," said Chandel, who recently wrote a review in Nature Cell Biology highlighting this idea. "An important implication of this work is that diseases linked to mitochondrial dysfunction like neurodegeneration or normal aging process might be due to elevation in metabolites like 2HG."

Explore further: Novel method enables absolute quantification of mitochondrial metabolites

More information: Elena Ans? et al. The mitochondrial respiratory chain is essential for haematopoietic stem cell function, Nature Cell Biology (2017). DOI: 10.1038/ncb3529

Whitehead Institute scientists have developed a method to quickly isolate and systematically measure metabolite concentrations within the cellular organelles known as mitochondria, often referred to as the "powerhouses of ...

A new University of Colorado Boulder study shows for the first time the final stages of how mitochondria, the sausage-shaped, power-generating organelles found in nearly all living cells, regularly divide and propagate.

Using yeast cells as a model, scientists from the A.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University investigated the mechanisms that allow cells to protect themselves from invasion of ...

Researchers at NYU Langone Medical Center have discovered that mitochondria, the major energy source for most cells, also play an important role in stem cell developmenta purpose notably distinct from the tiny organelle's ...

Aging, neurodegenerative disorders and metabolic disease are all linked to mitochondria, structures within our cells that generate chemical energy and maintain their own DNA. In a fundamental discovery with far-reaching implications, ...

Researchers at UT Southwestern Medical Center have uncovered the mechanism that cells use to find and destroy an organelle called mitochondria that, when damaged, may lead to genetic problems, cancer, neurodegenerative diseases, ...

There are many ways to make a living in a suitable climate but far fewer in a less suitable one. That may seem obvious for people living under various socio-economic stresses, but new research shows it also applies to the ...

Adult females and males in a newly identified genus of Latin American praying mantises have evolved sharply different camouflage strategies, according to a Cleveland Museum of Natural History-led study published in the journal ...

Male birds tend to be better singers than femalesbut does the basis for this difference lie in the brain or in the syrinx, the bird equivalent of our larynx? The researchers behind a new study from The Auk: Ornithological ...

Animals living in areas where conditions are ideal for their species have less chance of evolving to cope with climate change, new research suggests.

The arrangement of the photoreceptors in our eyes allows us to detect socially significant color variation better than other types of color vision, a team of researchers has found. Specifically, our color vision is superior ...

Using high magnification imaging, a team of researchers has identified several never before seen structures on bacteria that represent molecular machinery. The research is published this week in the Journal of Bacteriology, ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to read the rest:
Mitochondria behind blood cell formation - Phys.org - Phys.Org

Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic … – The Scientist

Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic ...
The Scientist
Cambridge, UK, 14 June 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the Company), the world leader in the application of gene editing technologies, today announces progress of its gene and cell therapy platform for contract service and ...

and more »

Link:
Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic ... - The Scientist

Global Autologous Cell Therapy Market – Analysis, Technologies & Forecasts to 2021 – Increasing Demand for Effective … – Business Wire (press…

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Autologous Cell Therapy Market 2017-2021" report to their offering.

The global autologous cell therapy market to grow at a CAGR of 23.39% during the period 2017-2021.

The report, Global Autologous Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

The latest trend gaining momentum in the market is private funding will fuel market growth. The increasing investments from private enterprises will likely change the market dynamics. Many vendors are investing in production or manufacturing facilities to improve their production or manufacturing expertise. They are also focusing on establishing new business units or companies to penetrate the market further.

According to the report, one of the major drivers for this market is increasing demand for effective drugs for cardiac and degenerative disorders. There has been an increased demand for providing effective drugs for cardiac and degenerative disorders globally. Prior to the advent of autologous cell therapies, there was no effective drug to repair a damaged heart. The discovery of possible cardiac autologous cells opened new possibilities for repairing damaged cardiac tissue caused by acute myocardial infarction or coronary artery disease.

Key vendors

Other prominent vendors

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Pipeline Landscape

PART 06: Market landscape

PART 07: Market segmentation by application

PART 08: Market Segmentation by therapy

PART 09: Geographical segmentation

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/633cdq/global_autologous

Visit link:
Global Autologous Cell Therapy Market - Analysis, Technologies & Forecasts to 2021 - Increasing Demand for Effective ... - Business Wire (press...

Former Kilkenny star Richie Power hoping stem-cell therapy can fix … – The Irish Sun

Power was forced to retire from inter-county hurling with the injury two years ago at the age of 29

RICHIE POWER hopes radical new stem-cell therapy in Croatia can fix his battered knee.

The eight-time All-Ireland medallist with Kilkenny retired in the wake of the 2015 Liam MacCarthy triumph at the age of just 29.

Power had three operations on his left knee that year alone and admits rushing back too soon ultimately ended his career.

The speedy attacker got back to Croke Park in February with AIB All-Ireland intermediate club champions Carrickshock.

But he has not played for them since and his quality of life has suffered with his knee causing him constant pain.

Ex-Kilkenny hurler David Byrne, who works with an American company linked to a hospital in Zagreb, put Power on the stem-cell trail.

Power said: The process is about regenerating cartilage in the left knee.

They take some good cartilage from the right knee, bring it into the lab and more or less clone it.

Then they inject it back into your left knee and you are hoping then that the blood will run to it and regenerate there.

From what I gather, youre not looking at a huge period of time out.

You have two or three months to help it and they bring you back over every three months for a check-up to see if its working.

The big issue is that I dont think theres anyone who has stood over it and said, Yeah, it definitely works, because they are waiting to see five, ten, 15 years down the line as to how it helps.

The feedback has been positive. Its worth a try.

The former Cats star is not looking to revive his county career though even if Kilkenny could do with him.

He is simply looking for a better quality of life and to extend his club career by a few more years.

Power added: If I dont get anything done in Croatia and if I decide to go back playing for another year or two and keep struggling through, then Im probably looking at a knee replacement by the time Im 40.

Im only 31 so its not something I want to face at such a young age.

It is just to try to give me an extra 15 or 20 years with my own knee.

If they can do that then great, it will be well worth it. If not, then I need to make a decision and maybe hang up the boots altogether.

More here:
Former Kilkenny star Richie Power hoping stem-cell therapy can fix ... - The Irish Sun

Kilkenny legend Richie Power: ‘Stem-cell treatment is my last hurrah … – Independent.ie

Following extensive research the eight-time All-Ireland winner has opted to take a leaf out of the book of many American Football players and hopes such therapy can help prolong an inevitable knee replacement.

To keep hurling with Carrickshock would be a bonus but doing the simple things in life without pain is what really attracted him to Zagreb clinic (which costs "under 1,000") in what he admits is "a last hurrah" after six operations.

"It's regenerating the cartilage in the left knee. They take some good cartilage from the right knee, bring it into the lab and more or less clone it.

"Then they inject it back into your left knee and you are hoping that the blood will run to it and regenerate there," the 31-year-old former Kilkenny star said.

"It's not to get back playing. It's just to get a quality of life with my own knee. Some days I'd find it hard to go and puck around with Rory (his son) like.

"That makes it very hard. It's for things like that as the years go on. I'm probably looking at a knee replacement by the time I'm 40.

"It is just to try and give me an extra 15-20 years with my own knee and if they can do that then great, it will be well worth it. If not I need to make a decision and maybe end up hanging up the boots altogether. Look, if it has to be done it has to be done.

"I'd like to be in a position where I am completely pain-free. I'd like to maybe run around and not worry about the leg going under me. I went to see everyone. I sat down with the Aussie Rules doctors and teams when they were here and absolutely everyone and anyone that I could. This is the last hurrah. If it doesn't work, it doesn't work."

Subscribe to The Throw-In, Independent.ie's weekly Championship podcast, for the best in GAA discussion and analysis every Monday, with some of the biggest names in football and hurling from Joe Brolly, Toms 'S, Brendan Cummins and John Mullane.

See more here:
Kilkenny legend Richie Power: 'Stem-cell treatment is my last hurrah ... - Independent.ie

Hong Kong biotech start-up claims world first in stem cell treatment of Alzheimer’s and Parkinson’s diseases – South China Morning Post

Oper Technology, a Hong Kong biotechnology start-up, has pioneered what it claims is a world first in stem cell treatment that it says could potentially help millions of patients suffering from Alzheimers and Parkinsons diseases.

The business was co-founded by Hong Kong Baptist Universitys Professor Ken Yung, who specialises in neurobiology and neurological diseases in the universitys biology department.

He and his team has now developed a method of harvesting neural stem cells from the brains of live subjects using specially developed nanoparticles.

The exploration of using stem cells to repair damaged neural cells is not a new concept. Scientists in the US and elsewhere have experimented using stem cells from fat and skin, developing them into neural cells.

But Yung claims his team is the first to successfully harvest stem cells directly from the brain and re-inject the developed neural cells back into a live subject, thereby artificially regenerating any cells which have died off, due to neurological diseases from neural stem cells themselves.

Stem cells have the potential to develop into different types of cells with specialised functions.

The nanoparticles which are made of a type of iron oxide work like magnets to attract the stem cells within the brain.

Yung said these can then be developed into more specific neural cells and re-injected into the brain to replace damaged cells caused by diseases such as Alzheimers and Parkinsons, where neurons in the patients brains progressively die off with time.

He suggests the treatment could benefit almost 100 million patients around the world, who suffer from neurodegenerative diseases, including strokes.

China alone has the largest population of people with dementia, with an estimated 23.3 million now projected to suffer from the condition by 2030, according to the World Health Organisation.

Yung co-founded Oper Technology and serves as its chairman.

The company is being developed under Hong Kong Science and Technology Parks Incu-Bio programme, which provides select biotechnology start-ups with laboratory and support services, and ultimately it aims to commercialise its medical technology.

If you put the [developed] cells in a different environment from where the [stem cells are harvested], there might be [misdirected] growth in an uncontrolled environment, said Yung.

We want to use neural cells to repair neural cells, and since the stem cells and re-injected neural cells are from the same micro-environment, there will not be uncontrollable growth.

The method has proven to be very successful when tested on rats, especially in cases of Parkinsons, according to Yung, who suggested the method could eventually become an ultimate treatment for the disease.

Furthermore, the risks of this treatment are similar to what is currently on the market today, he added.

The treatment could also help to treat early-stage Alzheimers patients, slowing down or even halting the degeneration process, although Yung acknowledged that its effectiveness in treating terminal stage patients may be limited since it would be difficult to regenerate enough neural cells when patients brains have shrunk due to the condition.

While animals subjected to the treatment displayed an improvement in neural function following the re-injection, the team has yet to start on clinical trials as such cell therapy is still nascent and largely unregulated in Hong Kong.

Oper Technology is currently seeking investment and often sets up booths at conferences such as last weeks EmTech Hong Kong conference, which focuses on innovation and emerging technologies.

Yung hopes to raise enough funds to begin clinical trials in Australia in the near future, where autologous cell therapies are legal and thus provides an ideal environment for clinical trials.

Read the original here:
Hong Kong biotech start-up claims world first in stem cell treatment of Alzheimer's and Parkinson's diseases - South China Morning Post

Stem Cell Therapy Becomes Law in Texas – PR Newswire (press release)

"At StemGenex, we are committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells," said Alexander. "Specifically, we use adipose-derived adult stem cell therapy for patients battling conditions such as Multiple Sclerosis, Parkinson's disease, COPD, Rheumatoid Arthritis and Osteoarthritis. We are also committed to the science of stem cell therapy and sponsor five clinical outcome studiesregistered with theNational Institute of Health (NIH) for these diseases."

"What I personally witnessed before the start of StemGenex were patients who had exhausted conventional medical treatments but wanted to try alternative therapies. I was one of them, suffering from severe Rheumatoid Arthritis. Ihad only three options; I could seek a clinical trial, travel to outside of the U.S. to try alternative therapies such as stem cell treatment or petition the FDA for access to drugs under the agency's "expanded access," or "compassionate use" program. Now, new state laws like the one just passed in Texas, built on model legislation from the Goldwater Institute in Arizona, will allow doctors and patients to make their own informed decisions on treatments that have cleared the safety phase of FDA testing."

Last year, in a move that was seen by some as a response to "Right to Try" laws, the 21st Century Cures Act, a landmark piece of legislation focused on medical innovation and medical research, was signed into law by President Obama. This Act provides the FDA with the flexibility to accelerate how it evaluates regenerative medicine treatments, such as stem cell therapies, while maintaining its high standards of safety and efficacy.

"We're on the cusp of a major change on how patients can access stem cell therapy," saidAlexander. "Today, new treatments and advances in research are giving new hope to people affected by a wide range of autoimmune and degenerative illnesses," said Alexander. "StemGenex Medical Group is proud to offer the highest quality of care and to potentially help those with unmet clinical needs improve their quality of life."

ABOUT StemGenex Medical Group

StemGenex Medical Group is committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex provides stem cell therapy options for individuals suffering with inflammatory and degenerative illnesses. Committed to the science and innovation of stem cell treatment,StemGenex sponsors five clinical outcome studiesregistered with theNational Institutes of Health (NIH) for Multiple Sclerosis, Parkinson's Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (COPD) and Osteoarthritis. These have been established to formally document and evaluate the quality of life changes in individuals following adipose-derived stem cell treatment.

Contact: Jamie Schubert, Director of Media & Community Relations jschubert@StemGenex.com, (858) 242-4243

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stem-cell-therapy-becomes-law-in-texas-300472809.html

SOURCE StemGenex Medical Group

http://www.stemgenex.com

Read more here:
Stem Cell Therapy Becomes Law in Texas - PR Newswire (press release)